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Abstract 
Case report on JMML evolving to AML in a 14-year-
old male acquiring an additional i(X)(q10). 
Clinics 
Age and sex 
14 years old male patient. 
Previous history 
preleukemia The patient is a 14-year-old male who 
was initially presented at age 12 years 4 month with 
anemia, leukocytosis, and splenomegaly, when he 
was diagnosed with juvenile myelomonocytic 
leukemia (JMML).  
Chromosome analysis of bone marrow revealed loss 
of chromosome 7 (45,XY,-7). The patient achieved 
complete remission after bone marrow 
transplantation from a female donor following 
chemotherapy. At the follow-up visit, 7.5 months 
after BMT and 10 month after initial visit (AIV), he 
was found to have 31% blasts in his peripheral blood 
smear. Bone marrow evaluation was consistent with 
acute myeloid leukemia (AML) arising out of 
JMML. Eighteen months AIV the karyotype of 
45,XY,-7[9]/45,Y,i(X)(q10),-7[11] was recorded. 
Chromosome analysis of bone marrow samples 21 
and 23 month AIV showed similar karyotypes. 
Previous malignancy  
No inborn condition of note  
No main items  
Blood 
WBC: 66.2X 109/l 
HB : 9.7g/dl 
Platelets : 42X 109/l 
Blasts : 31% 
Bone marrow: Hypercellular bone marrow (100%), 
with normal number of megakaryocytes with 
dyspoiesis, decreased erythropoiesis, increased and 
left shifted granulopoiesis, and 16% blasts. 
Cyto-Pathology 
Classification 
Immunophenotype 
JMML leading to AML. Multicolor flow cytometric 
analysis reveals two abnormal populations: The first 
abnormal population was 36% large monocytic cells 
with the following immunophenotype: bright 
CD11b+, heterogeneous CD13+, CD14+, dim 
CD15+, heterogeneous CD16+, CD33+, CD36+, 
CD38+, bright CD45+, bright CD56+, CD64+, 
partial dim CD71+, CD117+ and heterogeneous 
HLA-DR+. These cells were negative for CD7 and 
CD34. CD61 is uniformly positive. It was unclear if 
this was due to high background staining from 
platelets versus aberrant expression. The second 
abnormal population was 4% large myeloid blasts 
with the following immunophenotype: CD7+, 
CD11B+, CD33+, CD34+, dim CD45+, CD117+, 
heterogeneous CD38+, heterogeneous CD56+, 
partial dim CD71+, and heterogeneous HLA-DR+. 
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These cells are negative for CD13, CD14, CD15, 
CD16, CD36, CD61, and CD64. The analysis also 
identified 7.6% granulocytes. 
Pathology 
4% atypical myeloid blasts (with expression of 
CD7,CD11b, heterogeneous CD56, heterogeneous 
HLA-DR and heterogeneous CD38 and lack of 
CD13) and an increased population of atypical 
monocytic cells (36%) (with expression of bright 
CD56, CD117 and heterogeneous HLA-DR). 
Electron microscopy 
None 
Diagnosis 
Acute myeloid leukemia (AML) arising out of 
juvenile myelomonocytic leukemia (JMML). 
Survival 
Treatment 
Initially patient was diagnosed with JMML. The 
splenectomy followed by 2 cycles (28 days each) of 
low dose chemotherapy (consistent of oral 
mercaptopurine, cis-retinoic acid, low dose 
cytarabine).  
This is followed by allogeneic bone marrow 
transplant from HLA matched unrelated female 
donor.  
Preparative (conditioning) myeloablative regimen 
performed with busulfan, fludarabine, 
antithymocyte globulin (ATG) and graft versus host 
disease prophylaxis with mycophenolate mofetil and 
tacrolimus. BMT was performed after 2.5 month 
AIV and neutrophil engraftment was on day +26 and 
platelet engraftment on day +24 post-transplant. 
After BMT the patient received multiple courses of 
different chemotherapy and immunotherapy in order 
to achieve remission. Secondary AML arising from 
JMML was diagnosed after 10 month AIV and 
standard induction chemotherapy for AML was 
started (A10D3E5 according to COG-AML1031), 
due to failure to achieve remission status different 
agents in different combinations were administered 
including the following: Azacitadine, oral 
mercaptopurine, decitabine, lenalidomide, cis-
retinoic acid, low dose cytarabine, high-dose 
cytarabine and mitoxantrone, hydroxyurea. First 
i(X)(q10) appearance was recorded after 18 month. 
Eventually the patient underwent a second bone 
marrow transplant with a different donor 23 month 
AIV, conditioning with fludarabine and total body 
irradiation. He is currently awaiting count recovery. 
Treatment related death : no   
Phenotype at relapse: AML 
Status: Alive 
Survival: 23months 
Karyotype 
Sample: BM 
Culture time: 24h 
Banding: G-banding 
Results 
45,XY,-7[9]/45,Y,i(X)(q10),-7[11]. Twenty cells 
were analyzed and two cell lines were detected. Nine 
(9/20=45%) cells (clone 1) had a modal number of 
45 chromosomes, including the X and Y 
chromosomes.  
These cells were missing a chromosome 7 [45,XY,-
7]. The remaining eleven (11/20=55%) cells (clone 
2) had a modal number of 45 chromosomes, 
including a Y chromosome, an isochromosome of 
the long arm of X chromosome, and monosomy 7 
[45,Y,i(X)(q10),-7]. 
Other molecular cytogenetics technics 
Fluorescence in situ hybridization (FISH). 
Other molecular cytogenetics results 
nuc ish(D7Z1,D7S522)x1[285/300]  
Fluorescence in situ hybridization (FISH) studies 
were performed on 300 nuclei using the DNA probes 
D7S522/CEP 7 [7q31/7cen]. This probe detects the 
D7S522 deletion [del(7)(q31)] in a fluorescence in 
situ hybridization dual color assay on cultured cells. 
The frequency of nuclei with a monosomy 7 signal 
pattern was 95.0%. 
Other Molecular Studies 
Technics: 
DNA Testing for FLT3 and NPM1 Mutations: PCR. 
Results: 
FLT3-ITD mutation: Not Detected; FLT3-D835 
tyrosine kinase domain mutation: Not Detected; 
NPM1 exon 12 mutation: Not Detected 
Other Findings 
Chronic cough, Pancytopenia due to antineoplastic 
chemotherapy Immunocompromised state, CKD 
(chronic kidney disease), stage 4 (severe), Bone 
marrow replaced by transplant, Trachea (stenosis), 
Nausea, S/P splenectomy, VRE (vancomycin 
resistant enterococcus) culture positive, Juvenile 
myelomonocytic leukemia, Palliative care patient, 
Fluid overload, Acidosis, Uremia, Vitamin D 
deficiency, Hyperparathyroidism, 
Hypoalbuminemia, Malnutrition due to renal 
disease, Hypophosphatemia, Poor appetite, 
Encounter for antineoplastic chemotherapy, 
Tracheal stenosis, Chronic renal failure in pediatric 
patient, stage 5, Tracheitis, Chronic renal failure in 
pediatric patient (unspecified stage) 
Comments 
Here we describe a 14 year old male patient who was 
initially diagnosed with JMML and a bone marrow 
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karyotype of (45,XY,-7[20]). He developed AML 
7.5 month post-BMT. After 18 month AIV the first 
i(X)(q10) detected. The karyotype of 45,XY,-
7[9]/45,Y,i(X)(q10),-7[11] recorded on month 21 
AIV. Structural anomalies of X chromosome in 
hematological malignancies (HM) are uncommon 
and occur in approximately 1-1.5% of patients 
(Dewald, GW. et al. 1989, Byrd, JC. et all 2002). The 
most common anomaly is isodicentric X with 
idic(X)(q13). The i(X)(p10) and i(X)(q10) are 
observed less frequently. Most isochromosome X, 
observed in HM are affecting females. The reported 
cases in males include i(X)(q10) in a 51-year-old 
man with common ALL (Bacher, U et al. 2009), a 
57-year-old man with Follicular Lymphoma (Donti, 
E. et al. 1988) and a man with DLBCL of unknown 
age (Itoyama, T. et al. 2002). 
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